PE20141048A1 - Combinacion que comprende umeclidinio y un corticosteroide - Google Patents

Combinacion que comprende umeclidinio y un corticosteroide

Info

Publication number
PE20141048A1
PE20141048A1 PE2013002753A PE2013002753A PE20141048A1 PE 20141048 A1 PE20141048 A1 PE 20141048A1 PE 2013002753 A PE2013002753 A PE 2013002753A PE 2013002753 A PE2013002753 A PE 2013002753A PE 20141048 A1 PE20141048 A1 PE 20141048A1
Authority
PE
Peru
Prior art keywords
corticosteroid
combination including
pharmaceutical product
combination pharmaceutical
umeclidinium
Prior art date
Application number
PE2013002753A
Other languages
English (en)
Inventor
Glenn Crater
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE20141048A1 publication Critical patent/PE20141048A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

SE REFIERE A UN PRODUCTO FARMACEUTICO DE COMBINACION EN FORMA DE UNA COMPOSICION DE POLVO SECO, QUE COMPRENDE: A) UN COMPUESTO DE FORMULA (I) EN DONDE X- ES UN ANION FARMACEUTICAMENTE ACEPTABLE TAL COMO CLORURO, BROMURO, YODURO, HIDROXIDO, SULFATO, ENTRE OTROS; Y B) FUROATO DE FLUTICASONA EN UNA CANTIDAD DE 100 mcg/DOSIS. DICHO PRODUCTO FARMACEUTICO DE COMBINACION ES UTIL PARA EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS O DEL APARATO RESPIRATORIO TALES COMO EL ASMA
PE2013002753A 2011-06-08 2012-06-01 Combinacion que comprende umeclidinio y un corticosteroide PE20141048A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161494600P 2011-06-08 2011-06-08

Publications (1)

Publication Number Publication Date
PE20141048A1 true PE20141048A1 (es) 2014-09-08

Family

ID=46201674

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013002753A PE20141048A1 (es) 2011-06-08 2012-06-01 Combinacion que comprende umeclidinio y un corticosteroide

Country Status (19)

Country Link
US (1) US20140113888A1 (es)
EP (1) EP2717868A1 (es)
JP (1) JP2014516062A (es)
KR (1) KR20140041699A (es)
CN (1) CN103582477A (es)
AU (1) AU2012266541A1 (es)
BR (1) BR112013031572A2 (es)
CA (1) CA2838030A1 (es)
CL (1) CL2013003497A1 (es)
CO (1) CO6821951A2 (es)
CR (1) CR20130643A (es)
DO (1) DOP2013000290A (es)
EA (1) EA201391618A1 (es)
IL (1) IL229633A0 (es)
MA (1) MA35406B1 (es)
MX (1) MX2013014399A (es)
PE (1) PE20141048A1 (es)
SG (1) SG195262A1 (es)
WO (1) WO2012168161A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2739352T3 (es) 2009-02-26 2020-01-30 Glaxo Group Ltd Formulaciones farmacéuticas que comprenden 4-{(1R)-2-[(6-{2-[(2,6-diclorobencil)oxi]etoxi}hexil)amino]-1-hidroxietil}-2-(hidroximetil)fenol
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
KR101797274B1 (ko) 2011-12-28 2017-11-13 아사히 가세이 가부시키가이샤 레독스 플로우 이차 전지 및 레독스 플로우 이차 전지용 전해질막
US9763965B2 (en) 2012-04-13 2017-09-19 Glaxosmithkline Intellectual Property Development Limited Aggregate particles
GB201222679D0 (en) * 2012-12-17 2013-01-30 Glaxo Group Ltd Pharmaceutical combination products
GB201305825D0 (en) 2013-03-28 2013-05-15 Vectura Ltd New use
ES2959699T3 (es) 2014-05-28 2024-02-27 Glaxosmithkline Ip Dev Ltd Furoato de fluticasona en el tratamiento de la EPOC
US20170119744A1 (en) 2014-06-18 2017-05-04 Cipla Limited Pharmaceutical Composition Comprising a Beta-2-Agonist and Anticholinergic Agent
CN107200734B (zh) * 2016-03-18 2019-12-24 益方生物科技（上海）有限公司 奎宁环衍生物及其制备方法和用途
TR201712424A2 (tr) * 2017-08-21 2019-03-21 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Kuru toz i̇nhalasyon bi̇leşi̇mleri̇
US20210353650A1 (en) * 2020-05-18 2021-11-18 Cai Gu Huang Pharmaceutical formulation containing remdesivir and its active metabolites for dry powder inhalation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
CA2156408C (en) 1993-03-17 2005-02-15 Daniel C. Duan Aerosol formulation containing a polyester dispersing aid
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
EA005992B1 (ru) 2000-08-05 2005-08-25 Глаксо Груп Лимитед S-ФТОРМЕТИЛОВЫЙ ЭФИР 6α,9α-ДИФТОР-17α-[(2-ФУРАНИЛКАРБОНИЛ)ОКСИ]-11β-ГИДРОКСИ-16α-МЕТИЛ-3-ОКСОАНДРОСТА-1,4-ДИЕН-17β-КАРБОТИОКИСЛОТЫ В КАЧЕСТВЕ ПРОТИВОВОСПАЛИТЕЛЬНОГО АГЕНТА
UA77656C2 (en) * 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
GB0201677D0 (en) 2002-01-25 2002-03-13 Glaxo Group Ltd Medicament dispenser
SE527191C2 (sv) * 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser av tiotropium och fluticason
PE20060259A1 (es) * 2004-04-27 2006-03-25 Glaxo Group Ltd Compuestos de quinuclidina como antagonistas del receptor de acetilcolina muscarinico
PE20060826A1 (es) * 2004-12-06 2006-10-08 Smithkline Beecham Corp Derivado oleofinico de 8-azoniabiciclo[3.2.1]octano y combinacion farmaceutica que lo comprende
GB0515584D0 (en) 2005-07-28 2005-09-07 Glaxo Group Ltd Medicament dispenser
AR058289A1 (es) 2005-12-12 2008-01-30 Glaxo Group Ltd Colector para ser usado en dispensador de medicamento
EP2197444A1 (en) * 2007-09-12 2010-06-23 Glaxo Group Limited Novel combination of therapeutic agents
ES2739352T3 (es) * 2009-02-26 2020-01-30 Glaxo Group Ltd Formulaciones farmacéuticas que comprenden 4-{(1R)-2-[(6-{2-[(2,6-diclorobencil)oxi]etoxi}hexil)amino]-1-hidroxietil}-2-(hidroximetil)fenol
GB0921075D0 (en) * 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents

Also Published As

Publication number Publication date
MA35406B1 (fr) 2014-09-01
CO6821951A2 (es) 2013-12-31
BR112013031572A2 (pt) 2017-03-21
CR20130643A (es) 2014-02-04
CN103582477A (zh) 2014-02-12
CL2013003497A1 (es) 2014-07-04
SG195262A1 (en) 2013-12-30
NZ618166A (en) 2016-01-29
CA2838030A1 (en) 2012-12-13
MX2013014399A (es) 2014-03-21
AU2012266541A1 (en) 2014-01-09
EP2717868A1 (en) 2014-04-16
KR20140041699A (ko) 2014-04-04
DOP2013000290A (es) 2014-03-16
JP2014516062A (ja) 2014-07-07
EA201391618A1 (ru) 2014-05-30
IL229633A0 (en) 2014-01-30
WO2012168161A1 (en) 2012-12-13
US20140113888A1 (en) 2014-04-24

Similar Documents

Publication Publication Date Title
PE20141048A1 (es) Combinacion que comprende umeclidinio y un corticosteroide
PH12016501439B1 (en) (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors
PH12014502363A1 (en) N-aryltriazole compounds as lpar antagonists
PH12014502789A1 (en) N-alkyltriazole compounds as lpar antagonists
MY176814A (en) Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
MX345928B (es) Composiciones terapeuticamente activas y metodos de uso de las mismas.
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
PE20120989A1 (es) Sales de disacarina, acido difumarico, acido d-1-hidroxi-2-naftoico y monobenzoico del 2-(4-((2-amino-4-metil-6-(pentilamino) pirimidin-5-il) metil) fenil) acetato de 4-(dimetilamino) butilo
PH12014502364A1 (en) Substituted pyrazole compounds as lpar antagonists
BR112015027017A2 (pt) composições farmacêuticas inaláveis e dispositivos inaladores que contêm as mesmas
CL2013002542A1 (es) Uso de una composicion farmaceutica inhalable que contiene glicopirrolato o una sal del mismo para el tratamiento o profilaxis de taquicardia en pacientes con enfermedad pulmonar obstructiva cronica, asma, fibrosis quistica y enfermedades relacionadas de las vias aereas.
PE20121467A1 (es) Formulacion de aerosol para la enfermedad pulmonar obstructiva cronica
NZ720328A (en) Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease
CR20140536A (es) Nueva dosificación y formulación
PH12014501545A1 (en) Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof
PE20150171A1 (es) Nueva forma de dosificacion y formulacion de abediterol
CR20130693A (es) Composición farmacéutica ortalmológica tópica que contiene regorafenib
CO7170176A2 (es) Nuevo compuesto que tiene la capacidad para inhibir la enzima deshidrogenasa11b-hidroxiesteroide tipo 1(11b-hsd1) o sal farmaceúticamente aceptable del mismo, método para producir el mismo, y composición farmaceútica que contiene el mismo como ingrediente activo
MX2015001657A (es) Compuestos de cianopirazol substituidos con receptores de acido lisofosfatidico (lpar).
NI201400138A (es) Nueva dosificación y formulación.
UY35900A (es) Nueva dosificación y formulación

Legal Events

Date Code Title Description
FC Refusal